Pilot study of efficacy and safety of Rikkunshito for adverse events (nausea, emesis and anorexia) caused by chemotherapy (modified MAID therapy) for high grade bone and soft tissue sarcomas.

Pilot study of efficacy and safety of Rikkunshito for adverse events (nausea, emesis and anorexia) caused by chemotherapy (modified MAID therapy) for high grade bone and soft tissue sarcomas. - Pilot study of Rikkunshito for adverse events caused by chemotherapy (modified MAID therapy).

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015113

Enrollment

Registered

2014-09-10

Start date

2014-09-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High-grade bone and soft tissue sarcomas

Interventions

Rikkunnshito 7.5g/day, 14days No Rikkunnshito

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with histologically-proved high-grade bone and soft tissue sarcoma Patients firstly applied modified MAID regimen Patients with healthy vital organs WBC >3000/mm3 and <20000/mm3 Neutrophils >1500/mm3 Hb >8.0g/dl Plat >8X104/mm3 Total Bil <2.0mg/dl ALT/AST <150IU/l Cr <1.5mg/dl Performance Status (ECOG) 0-2

Exclusion criteria

Exclusion criteria: 1. Patients with double cancer 2. Patients who took Kampo within 4 weeks 3. Patients with any other severe diseases 4. Pregnat patients 5. Other exclusionary comobidity

Design outcomes

Primary

Measure	Time frame
Nausea, emesis and anorexia (CTCAE ver4.0), EORTC QLQ-C30(version3)	—

Countries

Japan

Contacts

Public ContactTakahiro Goto

Tokyo Metropolitan Komagome Hospital Department of Musculoskeletal Oncology

goto-tky@cick.jp03-3823-2101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026